Quazepam

Quazepam
2
Clinical data
Trade namesDoral
AHFS/Drugs.comMonograph
MedlinePlusa684001
Pregnancy
category
  • AU: D
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability29–35%
MetabolismLiver
Elimination half-life39 hours
ExcretionKidney
Identifiers
  • 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.048.329 Edit this at Wikidata
Chemical and physical data
FormulaC17H11ClF4N2S
Molar mass386.79 g·mol−1
3D model (JSmol)
  • FC(F)(F)CN1C(=S)C/N=C(\c2cc(Cl)ccc12)c3ccccc3F
  • InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2 checkY
  • Key:IKMPWMZBZSAONZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Quazepam, sold under the brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s.[2] Quazepam is used for the treatment of insomnia, including sleep induction and sleep maintenance.[3] Quazepam induces impairment of motor function and has relatively (and uniquely) selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines (due to its novel receptor-subtype selectivity).[4][5] Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.[6]

It was patented in 1970 and came into medical use in 1985.[7]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ US Patent 3845039
  3. ^ Mendels J (February 1994). "Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients". The Journal of Clinical Psychiatry. 55 (2): 60–65. PMID 7915708.
  4. ^ Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, et al. (June 2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology. 25 (3): 143–151. PMID 16045197.{{cite journal}}: CS1 maint: overridden setting (link)
  5. ^ Ongini E, Parravicini L, Bamonte F, Guzzon V, Iorio LC, Barnett A (1982). "Pharmacological studies with quazepam, a new benzodiazepine hypnotic". Arzneimittel-Forschung. 32 (11): 1456–1462. PMID 6129857.
  6. ^ Roth T, Tietz EI, Kramer M, Kaffeman M (1979). "The effect of a single dose of quazepam (Sch-16134) on the sleep of chronic insomniacs". The Journal of International Medical Research. 7 (6): 583–587. doi:10.1177/030006057900700620. PMID 42593. S2CID 36725411.
  7. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 538. ISBN 9783527607495.